PR Newswire Clinical TrialsOriginal article
GlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development
Phase 1GNX1021Positive
AI Analysis
Summary
GlycoNex Inc. announced first patient dosing in the Phase I clinical trial of GNX1021, a novel glycan-targeting antibody-drug conjugate, in Japan.
Clinical Trial Data
Phase
Phase I
Patients
1
Outcome Details
First patient dosed in Phase I trial
Importance:5/10
Sentiment:
0.60
Phase_1_TrialADCGlycan_TargetingFirst_in_HumanJapan
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 3, 2026 1:00 AM